CDK/HDAC-IN-4

• UNSPSC Description:

  CDK/HDAC-IN-4 is a high selective dual cyclin-dependent kinase (CDK)/histone deacetylase (HDAC) inhibitor with IC50 values of 88.4 and 168.9 nM, respectively. CDK/HDAC-IN-4 exhibits antiproliferative capacities against hematological and solid tumor cells. CDK/HDAC-IN-4 also induces MV-4-11 cell Apoptosis and S cell cycle arrests. CDK/HDAC-IN-4 possesses a significant antitumor potency in the MV-4-11 xenograft model[1].

• Target Antigen:

  Apoptosis; CDK; HDAC

• Type:

  Reference compound

• Related Pathways:

  Apoptosis;Cell Cycle/DNA Damage;Epigenetics

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/cdk-hdac-in-4.html

• Smiles:

  ClC1=CN=C(C=C1C2=CC=CC(NCC3(CCOCC3)C#N)=N2)NC4=CN(N=C4)CC5=CC=C(C=C5)C(NC6=C(C=CC=C6)N)=O

• Molecular Weight:

  634.13

• References & Citations:

  [1]Saidahmatov A, et al. Discovery of Novel 2-Aminopyridine-Based and 2-Aminopyrimidine-Based Derivatives as Potent CDK/HDAC Dual Inhibitors for the Treatment of Refractory Solid Tumors and Hematological Malignancies. J Med Chem. 2024 Sep 12;67(17):15220-15245.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported